This inventor holds 71 USPTO granted patents and 20 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Monoclonal Antibodies (CPC class C07K). Top assignees: Alderbio Holdings LLC, H. Lundbeck A/s, Alder Biopharmaceuticals, Inc.. Active years: 2010-2026.
Inventors with similar research interests:
Company Filing History:
44 out of 98 
20 out of 511 
3 out of 8 
Years Active: 2010-2026
Areas of Expertise:
Title: **Benjamin H Dutzar: Innovator in PACAP Antibody Research**
Introduction:
Benjamin H Dutzar is a prominent inventor based in Seattle, WA, known for his significant contributions to the field of biomedical innovations. With an impressive portfolio of 68 patents, Dutzar has made remarkable strides in the development of treatments targeting PACAP-related conditions.
Latest Patents:
Dutzar's latest inventions focus on "Methods of treatment with anti-PACAP antibodies." The present invention is directed to antagonistic antibodies and antigen binding fragments that exhibit binding specificity for PACAP. These antibodies serve to inhibit, block, or neutralize various biological effects associated with PACAP, such as vasodilation. In several exemplary embodiments, these antibodies and their fragments may include specific V, V, and CDR polypeptides. Furthermore, the invention provides methodologies for utilizing these antagonistic anti-PACAP antibodies for the diagnosis, assessment, and treatment of diseases and disorders linked to PACAP, especially in conditions where antagonism of PACAP-related activities can provide therapeutic benefits, including headache and migraine indications.
Career Highlights:
Dutzar has been affiliated with prominent companies such as Alderbio Holdings LLC and H. Lundbeck A/S, where he has advanced his research and innovation in antibody therapies. His robust career is marked by a commitment to enhancing medical treatments through cutting-edge science.
Collaborations:
Throughout his career, Dutzar has collaborated with esteemed colleagues including John A. Latham and Leon F. Garcia-Martinez. These partnerships have fostered a rich exchange of ideas and innovation, contributing to the advancement of PACAP-related research.
Conclusion:
Benjamin H Dutzar stands out as a significant figure in the realm of biomedical inventions, particularly through his work on anti-PACAP antibodies. His ongoing contributions have the potential to revolutionize treatment options for conditions associated with PACAP, establishing him as a key innovator in this critical field.